Claritas Neurocloud™ Receives ANVISA Approval for AI-Powered Brain Imaging Analysis in Brazil
核心洞察
Claritas NucMed Technologies received approval from Brazil's ANVISA regulatory agency to market Neurocloud (搜索)™, an AI-powered software device for brain imaging analysis in PET, SPECT, and MRI scans.
The technology addresses growing demand for brain imaging driven by increasing prevalence of neurodegenerative diseases like Alzheimer's (搜索), Parkinson's (搜索), and dementia (搜索) in aging populations.
Neurocloud (搜索)™ provides automated quantification of brain abnormalities, hypo- and hypermetabolism areas, and grey/white matter atrophy to improve clinical workflow and diagnostic efficiency.
Claritas NucMed Technologies Ltd (搜索) announced that Brazil's regulatory agency ANVISA (Agência Nacional de Vigilância Sanitária) has approved Claritas Neurocloud (搜索)™ for supply in Brazil, marking a significant expansion for the AI-powered brain imaging analysis platform.
The London-based healthcare technology company specializes in state-of-the-art image enhancement, noise reduction, segmentation and quantification, and related AI technologies. Neurocloud (搜索)™ provides solutions for analysis, localization and quantification of conditions and related biomarkers in the brain using PET, SPECT and MRI brain imaging.
Addressing Growing Clinical Demand
The approval comes as demand for brain imaging and screening rapidly increases due to expanding clinical applications in neurological and psychiatric conditions. With increasing lifespans and rising aging populations, the incidence of cognitive and neurodegenerative diseases such as Alzheimer's (搜索), Parkinson's (搜索), and dementia (搜索) is becoming more prevalent.
Additionally, the recognition and rise in mental health conditions are contributing to the heightened demand for brain imaging. Detection, analysis, and diagnosis in these areas are leading to a greater need, emphasizing the importance and existing gap in detection and diagnosis.
Clinical Applications and Workflow Benefits
Claritas Neurocloud (搜索)™ can be used to determine the location of abnormal areas of patients' brains, quantify hypo- and hypermetabolism areas, and determine whether grey or white matter atrophy is within the expected range of the patient's age. The platform also aids in monitoring the evolution of neurodegenerative diseases.
The unbiased, objective identification and automated quantification of regions of interest in brain scans improves workflow, and aids clinicians to use their time more efficiently on making diagnostic decisions. The technology is agnostic to hardware and works with all scanner types and manufacturers.
Company Background
Claritas NucMed Technologies Ltd (搜索) is a subsidiary of Claritas HealthTech Ltd (搜索), based in London, United Kingdom. The company serves as the authorized distributor of Claritas iPET™, iPETcertum™, Claritas Neurocloud (搜索)™, iSPECTcardiac™, and other nuclear medicine devices globally.
Claritas HealthTech Ltd (搜索) conducts research and development in the fields of image enhancement, machine vision and artificial intelligence with a focus on medical image processing and AI assisted interpretation and diagnostics. The company aims to transform the diagnostics industry with powerful and effective software products created using image enhancement and AI technology enabling and assisting doctors and physicians to make accurate diagnosis and improve patient lives. All Claritas products are compliant with HIPAA, DPDPA and GDPR requirements.